Dr. Lal PathLabs IPO
Dr. Lal PathLabs IPO — date, price band, lot size & details 2015
Dr. Lal PathLabs listed on 23 Dec 2015 at ₹720, 30.9% above the ₹550 issue price.
Dr. Lal PathLabs is a Delhi based provider of diagnostic and related healthcare tests through a national network. Its total income was Rs 640.12 crore in FY2015.
Stock price
Dr. Lal PathLabs is listed — here is the live share price.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Timetable
Key dates from opening to listing. Today is 15 November.
- Open 08 Dec 2015
- Close 10 Dec 2015
- Allotment 19 Dec 2015
- Refund/credit TBA
- Listing 23 Dec 2015
Issue summary
The terms of the offer, as filed.
| IPO Dates | 8 to 10 Dec, 2015 |
|---|---|
| Price Band | ₹540 – ₹550 |
| Face Value | ₹10 |
| Lot Size | 20 Shares |
| Issue Size | ₹631.91 Cr |
| Sale Type | OFS only |
| Listing On | BSE, NSE |
| Registrar | MUFG Intime India Private Limited |
| Min Investment | ₹ 11,000 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 20 shares at the ₹550 cut-off. Drag to size your application.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 20 | ₹11,000 |
| Retail (max) | 18 | 360 | ₹1,98,000 |
| S-HNI (min) | 19 | 380 | ₹2,09,000 |
| S-HNI (max) | 90 | 1,800 | ₹9,90,000 |
| B-HNI (min) | 91 | 1,820 | ₹10,01,000 |
Strengths & risks
Drawn from the offer document — the case for and against, side by side.
Strengths · 4
- 01Total income rose from Rs 423.86 crore in FY2013 to Rs 640.12 crore in FY2015.
- 02Profit after tax rose from Rs 48.88 crore in FY2013 to Rs 87.97 crore in FY2015.
- 03EBITDA rose from Rs 89.20 crore in FY2013 to Rs 154.38 crore in FY2015.
- 04It had almost no borrowing, at Rs 0.01 crore in FY2014.
Risks · 5
- 01Diagnostics is a crowded market with many local labs and national chains; profit was Rs 33.32 crore in six months to September 2015.
- 02Growth depends on adding labs and collection centres, which needs steady investment; total assets were Rs 548.61 crore.
- 03The whole Rs 631.91 crore issue was an offer for sale, so none of it went to the company.
- 04Pricing pressure from rivals and hospital labs can cut margins; EBITDA was Rs 154.38 crore in FY2015.
- 05Promoters held 63.67% before the issue and 58.7% after it.
Three years of numbers
All figures in ₹ crore, as reported in the Dr. Lal PathLabs offer document.
| Metric | 30 Sep 2015 | 31 Mar 2015 | 31 Mar 2014 | 31 Mar 2013 |
|---|---|---|---|---|
| Assets | 548.61 | 449.18 | 331.31 | 252.12 |
| Total Income | 394.75 | 640.12 | 543.90 | 423.86 |
| Profit After Tax | 33.32 | 87.97 | 73.95 | 48.88 |
| EBITDA | 85.46 | 154.38 | 137.41 | 89.20 |
| NET Worth | 383.86 | 319.24 | 215.80 | 151.85 |
| Reserves and Surplus | 301.59 | 237.98 | 135.49 | 146.83 |
| Total Borrowing | 0.01 |
See how this IPO compares — view listing performance of all mainboard IPOs.
Valuation & key ratios
Ratios are for the latest full financial year reported in the Dr. Lal PathLabs RHP.
Where the money goes
How the company intends to use the proceeds of the issue.
Information about the usage of proceeds from the Dr. Lal PathLabs IPO will be updated shortly.
Dr. Lal PathLabs IPO Anchor Investors
26 anchor investors across 12 fund houses committed ₹191.40 Cr a day before the issue opened.
Anchor investors bid a day before the issue opens and are locked in after allotment, so a book weighted towards domestic mutual funds is generally read as a stronger signal than one filled by short-horizon funds. Browse every anchor investor scheme or fund house we track.
About the company
Through its nationwide network it offers patients and healthcare providers a broad range of diagnostic tests for core testing, patient diagnosis and the prevention, monitoring and treatment of disease.
It has built a national network of laboratories and patient service centres.
The IPO was Rs 631.91 crore and was entirely an offer for sale at Rs 550, the top of the Rs 540 to Rs 550 band, so the company received no money.
Interested in this IPO? Check the live subscription status or browse all upcoming mainboard IPOs.
The bankers & the filings
Who is running the book, and the documents this page is built from.
Dr. Lal PathLabs IPO Documents
Read the filings this page is built from.
Lead Manager Track Record
How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.
Kotak Mahindra Capital Company Limited
204 issues handledBest listing: Premier Energies (+120.0%). Weakest: Puravankara Projects (-22.5%).
Citigroup Global Markets India Pvt. Ltd
74 issues handledBest listing: Tata Technologies (+140.0%). Weakest: Puravankara Projects (-22.5%).
Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.
Company contact
Frequently asked
What is the GMP of Dr. Lal PathLabs?
The current Grey Market Premium is ₹0.
What is the Dr. Lal PathLabs IPO price band?
₹540 to ₹550, on a face value of ₹10.
When is the allotment?
The basis of allotment is 19 December 2015, with listing on 23 December 2015.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — MUFG Intime India Private Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
